Q3 2019
Released Nov 12, 2019, after the close
10-Q filed Nov 12, 2019, 43 days after period end · 0001104659-19-062585
Q3 2019 · 10-Q
Revenue$164.99K$164.99K — vs Q3 2018no prior Q2 2019 on file
Net Income-$3.06M-$3.06M N/M vs Q3 2018N/M vs Q2 2019
EPS Diluted-$0.12-$0.12 N/M vs Q3 2018N/M vs Q2 2019
Operating Income-$2,975,688N/M
Operating Cash Flowderived-$2,797,368N/M
Margins · derived
Operating margin-1803.6%
Net margin-1854.8%
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q3 2019 | Q3 2018 | Q3 2017 | Q3 2016 |
|---|---|---|---|---|
| Revenue | $164.99K | $0.00 | $0.00 | — |
| Net Income | -$3.06M | -$2.46M | -$4.70M | -$3.24M |
| EPS Diluted | -$0.12 | -$0.12 | -$0.22 | -$0.18 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lipocine Inc. · CIK 1535955 · Engraved from SEC EDGAR